Novo

Novo Nordisk has signed a licensing agreement for HRS-1596, an obesity and type 2 diabetes drug developed by Hengrui, and will pay a $300 million upfront; further payments are tied to milestones and could bring the deal value to as much as $2.6 billion. Novo obtains exclusive rights to develop, manufacture and commercialize worldwide outside mainland China, Hong Kong, Macau and Taiwan, while Hengrui will receive sales royalties. HRS-1596 is being evaluated for once-weekly oral dosing; Hengrui already has approval in China to conduct Phase 1 studies. The transaction is expected to close in the fourth quarter of 2026. » Więcej na finanzen.net

Novo Nordisk has signed a licensing agreement with Hengrui for the obesity drug HRS-1596 and will pay an upfront sum of USD 300 million; the total deal can reach up to USD 2.6 billion depending on milestones and sales royalties. Novo receives exclusive rights to develop, manufacture and commercialize the drug globally outside mainland China, Hong Kong, Macau and Taiwan, and will evaluate the potential for a once-weekly oral formulation. Hengrui has already obtained approval in China for Phase 1 studies; the transaction is expected to close in Q4 2026. » Więcej na finanzen.net

Novo Nordisk has signed a licensing deal for Hengrui’s obesity drug HRS-1596 and will pay a $300 million upfront; the total value could reach $2.6 billion if milestones are met. Novo receives exclusive rights to develop, manufacture and commercialize the drug worldwide outside mainland China, Hong Kong, Macau and Taiwan, while Hengrui will receive sales-based royalties. HRS-1596 is said to have the potential for once-weekly oral administration; a phase 1 study has already been approved in China. The transaction is expected to close in the fourth quarter of 2026. » Więcej na finanzen.net